Condition: Systemic Lupus Erythematosus (SLE) · Children · Blinatumomab · Sponsor: Mao Jianhua
The goal of this clinical trial is to learn if blinatumomab works to treat refractory or active systemic lupus erythematosus (SLE) in children and adults. It will also learn about the safety of blinatumomab. The main questions it aims to answer are: Does blinatumomab improve symptoms and disease activity in refractory/active SLE? What side effects or adverse events do participants experience when taking blinatumomab? Participants will: Receive two courses of blinatumomab injections over five consecutive days each Be monitored for 52 weeks to evaluate the treatment's safety and effectiveness Undergo regular blood tests and assessments of disease activity during follow-up visits Researchers will collect data on changes in serological markers, disease symptoms, and adverse events throughout the study.
This description comes directly from the study's public registry record.
Jianhua Mao, PhD, MD · 13516819071 · maojh88@zju.edu.cn
Xiaojing Zhang, MD · 15867172808 · 6510007@zju.edu.cn
Always discuss trial participation with your own doctor first.
| Children's Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| Children's Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06789107